Antifungal drug discovery: The process and outcomes

Future Microbiology

Volumn 9, Issue 6, 2014, Pages 791-805

  Calderone, Richard ^a   Sun, Nuo ^b   Gay Andrieu, Francoise ^a   Groutas, William ^c   Weerawarna, Pathum ^c   Prasad, Sridhar ^d   Alex, Deepu ^a   Li, Dongmei ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WICHITA STATE UNIVERSITY   (United States)

^d CalAsia Pharmaceuticals Inc   (United States)

Author keywords

antifungals; compound libraries; discovery; drug targets; repurposing

Indexed keywords

ANTIFUNGAL AGENT; NATURAL PRODUCT;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; DATA MINING; DRUG POTENTIATION; DRUG REPOSITIONING; DRUG SYNTHESIS; DRUG TARGETING; FUNGAL VIRULENCE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HAPLOINSUFFICIENCY; HOMOZYGOTE; HUMAN; IN VITRO STUDY; INCIDENCE; MEDICAL TECHNOLOGY; MOLECULAR LIBRARY; MYCOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS TECHNOLOGY; REVIEW; SACCHAROMYCES CEREVISIAE; STRUCTURAL HOMOLOGY; VIRTUAL REALITY; DRUG DEVELOPMENT; MYCOSES; PROCEDURES;

ANTIFUNGAL AGENTS; DRUG DISCOVERY; HUMANS; MYCOSES;

EID: 84904643046     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.32     Document Type: Review

References (76)

1. Brown GD, Denning DW, Gow NA et al. Hidden killers: Human fungal infections. Sci. Transl. Med. 4(165), 165rv13 (2012
2. H.R. 2182 (112th): Generating Antibiotic Incentives Now Act of 2011. www.govtrack.us/congress/bills/112/hr2182
3. Statements for 10 20 Initiative. www.idsociety.org/IDSA-Statements- for-10x20-Initiative
4. Proposed Rules from the US FDA. www.gpo.gov/fdsys/pkg/FR-2013-2006-2012/ pdf/2013-13865.pdf
5. Antibiotic Resistance Threats in the United States, 2013. www.cdc.gov/drugresistance/threatreport-2013/pdf/ar-Threats-2013-2508.pdf
6. Pfaller M. Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125(1 Suppl.), S3-S13 (2012
7. Clancy CJ, Yu VL, Morris AJ et al. Fluconazole MIC and the fluconazole dose/ MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49, 3171-3177 (2005
8. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation Data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24(2), 235-247(1997
9. Rodríguez-Tudela JL, Almirante B, Rodríguez-Pardo D et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51, 3599-3604 (1997
10. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: Analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46, 2620-2629 (2007
11. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with the presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56, 1724-1732 (2013).
12. Cuenca-Estrella M, Rodriguez-Tudela J. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungals in vitro. Expert Rev. Antinfect. Ther. 8, 267-276 (2010
13. Pfaller M, Castanheira M, Diekema D et al. Comparison of European Committee of antimicrobial susceptibility testing (EUCAST) and Etest methods with the CLSI broth microdilution method fo echinocandin susceptibility testing of Candida species. J. Clin. Microbiol. 48, 1592-1599 (2010
14. Pfaller M, Boyken L, Hollis R et al. Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical Laboratory Standards Institute for testing itraconzaole, posaconazole, and voriconazole against Aspergillus isolates. J. Clin. Microbiol. 49, 1110-1112 (2011
15. Butts A, Krysan D. Antifungal drug discovery: Something old and something new. PLoS Pathog. 8, e1002870 (2012
16. Alex D, Gay-Andrieu F, May J et al. Amino acid derived 1,2-benzisothiazolinone derivatives as novel small molecule inhibitors: Identification of potential genetic targets. Antimicrob. Agents Chemother. 56, 4630-4639 (2012
17. Molecular Libraries Program -Overview. htp://mli.nih.gov/mli/mlp-overview
18. UNM School of Medicine, Department of Pathology, Translational Antimicrobial Discovery. http://pathology.unm.edu/research/ faculty- laboratories/translationalantimicrobial-discovery/index.html
19. Ericson E, Gebbia M, Heisler L et al. Off-Target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet. 4(8), e1000151 (2008
20. Giaever G, Flaherty P, Kumm J et al. Chemogenomic profiling: Identifying the functional interactions of small molecules. Proc. Natl Acad. Sci. USA 101, 793-798 (2004
21. Dolan K, Montgomery S, Buchheit B et al. Antifungal action of tamoxifen: In vitro and in vivo activities and mechanistic characterization. Antimicrob. Agents Chemother. 53, 3337-3346 (2009
22. NIH/NCI Developmental Therapeutics Program. http://dtp.nci.nih.gov
23. Sun N, Li D, Fonzi W et al. Multidrug resistant transporter Mdr1p mediated uptake of a novel antifungal compound. Antimicrob. Agents Chemother. 57, 5931-5939 (2013
24. Lohberger A, Coste A, Sanglard D. Distinct roles of the drug resistance transcription factors TAC1, MRR1 and UPC2 from Candida albicans in virulence. Eukaryot. Cell 3(1), 127-142 (2013
25. Spitzer M, Griffiths E, Blakely K et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Systems Biol. 7, 499-522 (2011
26. Calderone R, Alex D, Groutas W: US61/793080 (2013
27. Cook N: US5623463 (2002
28. Stylianou M, Kulessky E, Lopes JP et al. Antifungal application of non-Antifungal drugs. Antimicrob. Agents Chemother. 58(2), 1087-1013 (2013
29. Delattin N, DeBrucker K, VanDamme K, Moert E, Marchand A. Repurposing as a means to increase the activity of amphotericin B and caspofungin. J. Antimicrob. Chemother. 69(4), 1035-1044 (2013
30. Breger J, Fuchs BB, Aperis G et al. Antifungal chemical compounds identified using a C. alegans pathogenicity assay. PLoS Pathog. 3, e18 (2007
31. Dou D, Alex D, Du B et al. Antifungal activity of a series of 1,2-benzisothiazol-3(2H)-one derivatives. Bioorg. Med. Chem. 19, 5782-5787 (2011
32. Hoepfner D, Karkaree S, Helliwell S et al. An integrated approach for identification and target validation of antifungal compounds active against Erg11p. Antimicrob. Agents Chemother. 56, 4233-4240 (2012
33. DiSanto R. Natural products as antifungal agents against clinically relevant pathogens. Nat. Prod. Rep. 27, 1084-1098 (2010
34. Roemer T, Xu D, Singh S et al. Confronting the challenges of natural product basedantifungal discovery. Chem. Biol. 18(2), 148-164 (2011
35. Lopez A, Parsons A, Nislow C et al. Chemical-genetic approaches for exploring the mode of action of natural products. Prog. Drug Res. 237, 239-271 (2008
36. Sardi J, Scorzoni L, Bernardi T et al. Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J. Med. Microbiol. 62(Pt 1), 10-24 (2013
37. Zhang L, Chang JJ, Zhang SL et al. Synthesis and bioactive evaluation of novel hybrids of metronidazole and berberine as new types of antimicrobial agents and their transportation behavior by human serum albumin. Bioorgan. Med. Chem. 21(14), 4158-4169 (2013
38. Li D, Zhang D, Quan H et al. Fluconazole assists berberine to kill fluconazole-resistant Candida albicans. Antimicrob Agents Chemother. 57, 6016-6027 (2013
39. DeBruker K, Cammue P, Thevissen K. Apoptosis-inducing antifungal peptides and proteins. Biochem. Soc. Trans. 39, 1527-1532 (2011
40. Maddaford SP. A medicinal chemistry perspective on structure-based drug design and development. Methods Mol. Biol. 841, 351-381 (2012
41. Caliandro R, Belviso DB, Aresta BM et al. Protein crystallography and fragment-based drug design. Future Med. Chem. 5, 1121-1140 (2013
42. Gillespie P, Goodnow R. The hit-To-lead process in Drug discovery. Ann. Rep. Med. Chem. 39, 293-304 (2004
43. Meanwell NA. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 24, 1420-1456 (2011
44. Leeson PD, Empfield JR. Reducing the risk of drug attrition associated with physicochemical properties. Ann. Rep. Med. Chem. 45, 394-407 (2010
45. Waring MJ. Lipophilicity in Drug discovery. Expert Opin. Drug Discov. 5, 235-248 (2010
46. Pellegatti M. Preclinical in vivo ADME studies in Drug development: A critical review. Expert Opin. Drug Metab. Toxicol. 8, 161-172 (2012
47. Hopkin A, Groom C. The druggable genome. Nat. Rev. Drug Dis. 1, 727-730 (2002
48. FunSpec. http://funspec.med.utoronto.ca
49. Xu D, Jiang B, Ketela T et al. Genome-wide fitness test and mechanisms of action studies on inhibitory compounds in Candida albicans. PLoS Pathog. 3, 835-848 (200
50. Oh J, Fung E, Schlecht U et al. Gene annotation and drug target discovery in Candida albicans with a tagged transposon mutant collection. PLoS Pathog. 6, e1001140 (2010
51. Abadio A, Kioshima E, Teixeira M et al. Comparative genomics allowed the identification of drug targets agains human fungal pathogens. BMC Genomics 12, 75 (2011
52. Hu W, Silllaots S, Lemieux S et al. Essential gene identification and drug target priotization in Aspergillus fumigatus. PLoS Pathog. 3, e24 (2007
53. Roemer T, Jiang B, Davison J et al. Large-scale essential gene identification in andida albicans and applications to antifungal drug discovery. Mol. Microbiol. 50, 67-81 (2003
54. Tripathi H, Lugman S, Meena A et al. Genomic identification of potential targets unique to Candida albicans for the discovery of antifungal agent. Curr. Drug Targets 5(1), 136-149 (2013
55. Ostrosky-Zeichner L, Casadevall A, Galgiani J et al. An insight into the antifungal pipeline: Selected new molecules and beyond. Nat. Rev. Drug Discov. 9, 719-727 (2010
56. Andrusiak K, Piotrowski JS, Boone C. Chemical-genomic profiling: Systematic analysis of the cellular targets of bioactive molecules. Bioorg. Med. Chem. 20, 1952-1960 (2012
57. Ruiz-Camps I. Combination therapy for invasive aspergillosis. Enferm. Infect. Microbiol. Clin. 29(Suppl. 2), 38-42 (2011
58. Morschhauser J, Barker KS, Liu TT et al. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3, e164 (2007
59. Cannon RD, Lamping E, Holmes AR et al. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22, 291-321 (2009
60. Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 75, 213-267 (2011
61. Lamoth F, Juvvadi P, Gehrke C, Steinbach W. In vitro activity of calcineurin and heat shock protein 90 inhibitors against Aspergillus fumigatus azole and echinocandin-resistant strains. Antimicrob. Agents Chemother. 57(2), 1035-1039 (2013
62. Lamoth F, Juvvadi P, Gehrke C et al. Transcriptional activation of heat shock 90 mediated via a proximam promoter regions as trigger of caspofungin resistance in Aspergillus fumigatus. J. Infect. Dis. 209(3), 473-481 (2013
63. Singh-Babak SD, Babak T, Diezmann S et al. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog. 8, e1002718 (2012
64. Singh SD, Robbins N, Zaas AK et al. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 5, e1000532 (2009
65. Steinbach WJ, Reedy JL, Cramer RA Jr et al. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat. Rev. Microbiol. 5, 418-430 (2007
66. Rezael Z, Khabnadideh S, Zomorodian K et al. Design, synthesis and antifungal activity of some new imidazole and triazole derivatives. Arch. Pharm. Chem. Life Soc. 344, 658-665 (2011
67. Karwa R, Wargo KA. Efungumab: A novel agent in the treatment of invasive candidiasis. Ann. Pharmacother. 43, 1818-1823 (2009
68. Yu X, Vazquez A, Levine A, Carpizo D. Allele-specific p53 mutant reactivation. Cancer Cell 21, 614-625 (2012
69. Frezza C, Martins C. From tumor prevention to therapy: Empowering p53 to fight back. Drug Res. Update 15, 258-267 (2012
70. Mabanglo M, Hast M, Lubock N et al. Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design. Protein Sci. 23(3), 289-301 (2013
71. Zhou M, Dong X, Shen N et al. Crystal structures of Saccharomyces cerevisiae tryptophanyl-TRNA synthease: New insights into the mechanism of tryptophan activation and implications for anti-fungal drug design. Nucleic Acids Res. 38, 3399-3413 (2010
72. Laggner C, Schiefer C, Fiechtner B, Poles G, Hoffmann D et al. Discovery of high-Affinity ligands of s1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening. J. Med. Chem. 48, 4754-4764 (2005
73. Oberoi JK, Wattal C, Goel N, Raveendran R, Datta S, Prasad K. Non albicans Candida species in blood stream infections in a tertiary care hospital. Indian J. Med. Res. 136, 997-1003 (2012
74. Kim M-N, Shin H, Sung H et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: Identification, antifungal susceptibility, and clinical features. Clin. Infect. Dis. 48, 57-61 (2009
75. Hull C, Purdy N. Non antifungal clinical drug interventions and human commensal fungi: What are we selecting?. Future Microbiol. 8, 813-816 (2013
76. Walker I. Interscience conference on antimicrobial agents and chemotherapy -50th Annual Meeting -research on promising new agents: Part 2. IDrugs 13, 746-748 (2010